Dashboard
Manage Tickers

RETAREATA PHARMACEUTICALS INC

Nasdaq reatapharma.com


$ 172.35 $ 0.04 (0.02 %)    

Monday, 25-Sep-2023 15:59:53 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 172.36
$ 172.36
$ 172.35 x 100
$ 172.37 x 200
$ 172.34 - $ 172.46
$ 21.83 - $ 172.46
1,988,594
na
7.15B
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2023 06-30-2023 10-Q
2 05-10-2023 03-31-2023 10-Q
3 02-24-2023 12-31-2022 10-K
4 11-08-2022 09-30-2022 10-Q
5 08-08-2022 06-30-2022 10-Q
6 05-10-2022 03-31-2022 10-Q
7 02-28-2022 12-31-2021 10-K
8 11-08-2021 09-30-2021 10-Q
9 08-09-2021 06-30-2021 10-Q
10 05-06-2021 03-31-2021 10-Q
11 03-01-2021 12-31-2020 10-K
12 11-09-2020 09-30-2020 10-Q
13 08-10-2020 06-30-2020 10-Q
14 05-11-2020 03-31-2020 10-Q
15 02-19-2020 12-31-2019 10-K
16 11-12-2019 09-30-2019 10-Q
17 08-08-2019 06-30-2019 10-Q
18 05-09-2019 03-31-2019 10-Q
19 02-28-2019 12-31-2018 10-K
20 11-07-2018 09-30-2018 10-Q
21 08-08-2018 06-30-2018 10-Q
22 05-08-2018 03-31-2018 10-Q
23 03-02-2018 12-31-2017 10-K
24 11-13-2017 09-30-2017 10-Q
25 08-14-2017 06-30-2017 10-Q
26 05-10-2017 03-31-2017 10-Q
27 03-03-2017 12-31-2016 10-K
28 11-14-2016 09-30-2016 10-Q
29 08-11-2016 06-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

upward-trajectory-for-biotechpharma-ma-sector-trends-towards-pre-pandemic-levels-forecasts-positive-for-2024
Upward Trajectory For Biotech/Pharma M&A: ...
12/29/2023 12:04:52

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 bill...

an-oversold-gold-miner-with-strong-fundamentals--its-relative-strength-index-is-below-20-and-its-piotroski-f-score-is-8
An Oversold Gold Miner With Strong Fundame...
10/05/2023 13:58:03

Paying Attention To Gold Miners On Zero Hedge on Monday, contributing editor “Quoth The Raven” suggested “paying urgent attent...

Core News & Articles
Reata Pharmaceuticals Stockholders Approve...
09/21/2023 14:14:11

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"...

Core News & Articles
Sanofi Said To Have Been Mystery Buyer In ...
08/15/2023 19:36:23

-Bloomberg

analyst-ratings-for-reata-pharmaceuticals
Analyst Ratings for Reata Pharmaceuticals
08/15/2023 19:00:31

cantor-fitzgerald-reiterates-neutral-on-reata-pharmaceuticals-maintains-172-price-target
Cantor Fitzgerald Reiterates Neutral on Re...
08/15/2023 14:26:49

Cantor Fitzgerald analyst Charles Duncan reiterates Reata Pharmaceuticals (NASDAQ:RETA) with a Neutral and maintains $172 pr...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
08/14/2023 17:35:22

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
08/08/2023 17:35:31

benzingas-top-ratings-upgrades-downgrades-for-august-1-2023
Benzinga's Top Ratings Upgrades, Downgrade...
08/01/2023 15:00:35

citigroup-downgrades-reata-pharmaceuticals-to-neutral-raises-price-target-to-1725
Citigroup Downgrades Reata Pharmaceuticals...
08/01/2023 11:42:54

Citigroup analyst Yigal Nochomovitz downgrades Reata Pharmaceuticals (NASDAQ:RETA) from Buy to Neutral and raises the price ...

barclays-downgrades-reata-pharmaceuticals-to-equal-weight-raises-price-target-to-172
Barclays Downgrades Reata Pharmaceuticals ...
08/01/2023 09:29:26

Barclays analyst Carter Gould downgrades Reata Pharmaceuticals (NASDAQ:RETA) from Overweight to Equal-Weight and raises the ...

baird-maintains-outperform-on-reata-pharmaceuticals-raises-price-target-to-173
Baird Maintains Outperform on Reata Pharma...
07/31/2023 19:58:10

Baird analyst Brian Skorney maintains Reata Pharmaceuticals (NASDAQ:RETA) with a Outperform and raises the price target from...

benzingas-top-ratings-upgrades-downgrades-for-july-31-2023
Benzinga's Top Ratings Upgrades, Downgrade...
07/31/2023 15:00:46

ladenburg-thalmann-downgrades-reata-pharmaceuticals-to-neutral-raises-price-target-to-1725
Ladenburg Thalmann Downgrades Reata Pharma...
07/31/2023 13:09:26

Ladenburg Thalmann analyst Matthew Kaplan downgrades Reata Pharmaceuticals (NASDAQ:RETA) from Buy to Neutral and raises the ...

jefferies-downgrades-reata-pharmaceuticals-to-hold-raises-price-target-to-1725
Jefferies Downgrades Reata Pharmaceuticals...
07/31/2023 09:25:37

Jefferies analyst Maury Raycroft downgrades Reata Pharmaceuticals (NASDAQ:RETA) from Buy to Hold and raises the price target...

crude-oil-edges-higher-colgate-palmolive-posts-upbeat-earnings
Crude Oil Edges Higher; Colgate-Palmolive ...
07/28/2023 18:30:06

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 250 points on Friday. The Dow tr...

12-health-care-stocks-moving-in-fridays-intraday-session
12 Health Care Stocks Moving In Friday's I...
07/28/2023 17:31:12

why-avantor-shares-are-trading-lower-by-10-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Avantor Shares Are Trading Lower By 10...
07/28/2023 17:07:41

Gainers Unique Fabricating, Inc. (NYSE: UFAB) shares jumped 113% to $0.4605 after gaining 12% on Thursday.

dow-surges-250-points-exxon-mobil-earnings-miss-expectations
Dow Surges 250 Points; Exxon Mobil Earning...
07/28/2023 16:08:19

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 250 points on Friday. The Dow traded up 0....

stifel-downgrades-reata-pharmaceuticals-to-hold-raises-price-target-to-1725
Stifel Downgrades Reata Pharmaceuticals to...
07/28/2023 16:01:12

Stifel analyst Annabel Samimy downgrades Reata Pharmaceuticals (NASDAQ:RETA) from Buy to Hold and raises the price target fr...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION